<DOC>
	<DOCNO>NCT00930163</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate effect lebrikizumab patient asthma remain inadequately control chronic therapy inhale corticosteroid ( ICS ) .</brief_summary>
	<brief_title>A Study Lebrikizumab ( MILR1444A ) Adult Patients With Asthma Who Are Inadequately Controlled Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Body weight 40 kg150 kg Chest radiograph evidence clinically significant abnormality Uncontrolled asthma Asthma exacerbation screen Known malignancy Known immunodeficiency Preexisting lung disease asthma Uncontrolled clinically significant medical disease Current smoker History substance abuse may impair risk patient 's full participation study , judgment investigator Prior allergic reaction monoclonal antibody Patients ( men woman ) reproductive potential willing use contraception Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adult Asthma</keyword>
</DOC>